{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:58Z","timestamp":1790096938544,"version":"4.0.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018385","name":"Max Planck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006590","name":"Sachsen-Anhalt Ministerium fur Wirtschaft Wissenschaft und Digitalisierung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104751","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:47:47Z","timestamp":1785307667000},"page":"104751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9059-496X","authenticated-orcid":false,"given":"Gunter","family":"Maubach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104751_b0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molcel.2024.12.015","article-title":"Ubiquitin\u2014a structural perspective","volume":"85","author":"Agrata","year":"2025","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104751_b0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","article-title":"Mechanisms of deubiquitinase specificity and regulation","volume":"86","author":"Mevissen","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.drudis.2026.104751_b0015","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1002\/mco2.736","article-title":"The role of ubiquitination in health and disease","volume":"5","author":"Liao","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.drudis.2026.104751_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2021.10.027","article-title":"Deubiquitinases: from mechanisms to their inhibition by small molecules","volume":"82","author":"Lange","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104751_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2025.1582049","article-title":"The role of deubiquitinases in cardiovascular diseases: mechanisms and therapeutic implications","volume":"12","author":"Fei","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.drudis.2026.104751_b0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41420-024-02237-3","article-title":"DUBs in Alzheimer\u2019s disease: mechanisms and therapeutic implications","volume":"10","author":"Qin","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2026.104751_b0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.molmed.2025.01.001","article-title":"Dysregulation of deubiquitinylases: a linchpin of gastrointestinal diseases","volume":"31","author":"Ferino","year":"2025","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.drudis.2026.104751_b0040","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303807","article-title":"Deubiquitylating enzymes in cancer and immunity","volume":"10","author":"Ren","year":"2023","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2026.104751_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70036","article-title":"Deubiquitinases as novel therapeutic targets for diseases","volume":"5","author":"Xian","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.drudis.2026.104751_b0050","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and\/or refractory multiple myeloma","volume":"38","author":"Rowinsky","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drudis.2026.104751_b0055","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2024.42.16_suppl.3005","volume":"42","author":"Yap","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104751_b0060","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/cancers15020517","article-title":"AtomNet-aided OTUD7B inhibitor discovery and validation","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2026.104751_b0065","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202004846","article-title":"SPOP and OTUD7A control EWS\u2013FLI1 protein stability to govern Ewing sarcoma growth","volume":"8","author":"Su","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2026.104751_b0070","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1535-7163.MCT-24-0515","article-title":"Characterization of TNG348: a selective, allosteric USP1 inhibitor that synergizes with PARP inhibitors in tumors with homologous recombination deficiency","volume":"24","author":"Simoneau","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104751_b0075","doi-asserted-by":"crossref","first-page":"e4398","DOI":"10.1002\/pro.4398","article-title":"Characterizing (un)binding mechanism of USP7 inhibitors to unravel the cause of enhanced binding potencies at allosteric checkpoint","volume":"31","author":"Srivastava","year":"2022","journal-title":"Protein Sci"},{"key":"10.1016\/j.drudis.2026.104751_b0080","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1021\/acs.jcim.4c01400","article-title":"Rational computational workflow for structure-guided discovery of a novel USP7 inhibitor","volume":"65","author":"Srivastava","year":"2025","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2026.104751_b0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104751_b0090","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200690","article-title":"EFMC: trends in medicinal chemistry and chemical biology","volume":"24","author":"Auberson","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.drudis.2026.104751_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202318849","article-title":"N-cyanopiperazines as specific covalent inhibitors of the deubiquitinating enzyme UCHL1","volume":"63","author":"Schmidt","year":"2024","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drudis.2026.104751_b0100","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acschembio.3c00805","article-title":"Reversible covalent inhibition\u2500desired covalent adduct formation by mass action","volume":"19","author":"Patel","year":"2024","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0105","article-title":"A chemoproteomic platform for selective deubiquitinase inhibitor discovery","volume":"4","author":"Cookson","year":"2023","journal-title":"Cell Rep Phys Sci"},{"key":"10.1016\/j.drudis.2026.104751_b0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1039\/D4CB00029C","article-title":"Discovery of potent and selective activity-based probes (ABPs) for the deubiquitinating enzyme USP30","volume":"5","author":"Mondal","year":"2024","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0115","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1021\/acsptsci.4c00331","article-title":"Cell-based covalent-capture deubiquitinase assay for inhibitor discovery","volume":"7","author":"Doleschal","year":"2024","journal-title":"ACS Pharm Transl Sci"},{"key":"10.1016\/j.drudis.2026.104751_b0120","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/med.70001","article-title":"The discovery of cryptic pockets increases the druggability of \u2018undruggable\u2019 proteins","volume":"45","author":"Mou","year":"2025","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2026.104751_b0125","article-title":"Recent computational advances in the identification of cryptic binding sites for drug discovery","volume":"5","author":"Ga\u0161par\u00edkov\u00e1","year":"2025","journal-title":"Bioinform Adv"},{"key":"10.1016\/j.drudis.2026.104751_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116161","article-title":"Recent advances in the development of deubiquitinases inhibitors as antitumor agents","volume":"266","author":"Zheng","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0135","series-title":"Conjugation and Deconjugation of Ubiquitin Family Modifiers: Subcellular Biochemistry","first-page":"69","article-title":"Mechanism, specificity and structure of the deubiquitinases","author":"Komander","year":"2010"},{"key":"10.1016\/j.drudis.2026.104751_b0140","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1021\/jacs.0c10513","article-title":"Exploring the versatility of the covalent thiol\u2013alkyne reaction with substituted propargyl warheads: a deciding role for the cysteine protease","volume":"143","author":"Mons","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104751_b0145","doi-asserted-by":"crossref","DOI":"10.1002\/cphc.202300596","article-title":"Molecular mechanism of labelling functional cysteines by heterocyclic thiones","volume":"25","author":"Mihalovits","year":"2024","journal-title":"ChemPhysChem"},{"key":"10.1016\/j.drudis.2026.104751_b0150","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41467-023-36246-0","article-title":"Accelerating inhibitor discovery for deubiquitinating enzymes","volume":"14","author":"Chan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104751_b0155","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.chembiol.2011.08.018","article-title":"Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes","volume":"18","author":"Altun","year":"2011","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0160","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1038\/s41598-020-62076-x","article-title":"Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism","volume":"10","author":"Schauer","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104751_b0165","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/cbdd.12571","article-title":"Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15","volume":"86","author":"Wang","year":"2015","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2026.104751_b0170","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cbic.201900434","article-title":"Ubiquitin C-terminal hydrolase L1: biochemical and cellular characterization of a covalent cyanopyrrolidine-based inhibitor","volume":"21","author":"Krabill","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.drudis.2026.104751_b0175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40364-021-00320-w","article-title":"Deubiquitinases in hematological malignancies","volume":"9","author":"Lei","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.drudis.2026.104751_b0180","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104751_b0185","doi-asserted-by":"crossref","first-page":"14693","DOI":"10.1021\/acs.jmedchem.4c01721","article-title":"Demystifying functional parameters for irreversible enzyme inhibitors","volume":"67","author":"Heppner","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0190","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.1021\/jacs.0c04527","article-title":"Discovery of a potent and selective covalent inhibitor and activity-based probe for the deubiquitylating enzyme UCHL1, with antifibrotic activity","volume":"142","author":"Panyain","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104751_b0195","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1038\/s41467-022-33559-4","article-title":"Structural basis for specific inhibition of the deubiquitinase UCHL1","volume":"13","author":"Grethe","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104751_b0200","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1021\/acs.jproteome.4c00618","article-title":"Structural dynamics of the ubiquitin specific protease USP30 in complex with a cyanopyrrolidine-containing covalent inhibitor","volume":"24","author":"O\u2019Brien","year":"2025","journal-title":"J Proteome Res"},{"key":"10.1016\/j.drudis.2026.104751_b0205","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000768","article-title":"USP30 sets a trigger threshold for PINK1\u2013PARKIN amplification of mitochondrial ubiquitylation","volume":"3","author":"Rusilowicz-Jones","year":"2020","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.drudis.2026.104751_b0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1681\/ASN.20233411S127a","article-title":"MTX652, a novel selective USP30 Inhibitor for the treatment of AKI: Phase 1 results in healthy subjects and model-driven human efficacious dose projections: TH-OR93","volume":"34","author":"Aceves","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.drudis.2026.104751_b0215","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1038\/s41467-023-42876-1","article-title":"Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson\u2019s disease mouse model","volume":"14","author":"Fang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104751_b0220","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"D'Arcy","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104751_b0225","doi-asserted-by":"crossref","first-page":"26979","DOI":"10.1038\/srep26979","article-title":"The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104751_b0230","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1021\/acs.jmedchem.2c01933","article-title":"Discovery and characterization of BAY-805, a potent and selective inhibitor of ubiquitin-specific protease USP21","volume":"66","author":"G\u00f6ricke","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0235","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq6353","article-title":"Cryo-EM reveals a mechanism of USP1 inhibition through a cryptic binding site","volume":"8","author":"Rennie","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2026.104751_b0240","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9932996","article-title":"Identifying USP1 inhibitors with allosteric effect on its triple catalytic center through virtual screening","volume":"2023","author":"Xu","year":"2023","journal-title":"J Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0245","doi-asserted-by":"crossref","first-page":"15557","DOI":"10.1021\/acs.jmedchem.4c01184","article-title":"Structural and biochemical insights into the mechanism of action of the clinical USP1 inhibitor, KSQ-4279","volume":"67","author":"Rennie","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0250","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1021\/acs.jmedchem.0c00245","article-title":"Discovery of potent, selective, and orally bioavailable inhibitors of USP7 with in vivo antitumor activity","volume":"63","author":"Leger","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0255","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1021\/acs.jmedchem.4c02792","article-title":"Discovery and optimization of a series of novel morpholine-containing USP1 inhibitors","volume":"68","author":"Zhang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109820","article-title":"Discovery and optimization of 1H-pyrazolopyrimidine-3-carboxamide derivatives as USP1 inhibitors for BRCA1-mutant cancer treatment","volume":"175","author":"Zhao","year":"2026","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0265","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1021\/jm5010495","article-title":"Synthesis and structure\u2013activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1\/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer","volume":"57","author":"Dexheimer","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0270","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nchembio.1455","article-title":"A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses","volume":"10","author":"Liang","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0275","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","article-title":"The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination-deficient tumors","volume":"84","author":"Cadzow","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104751_b0280","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2017.09.003","article-title":"Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7","volume":"24","author":"Lamberto","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nchembio.2528","article-title":"Discovery and characterization of highly potent and selective allosteric USP7 inhibitors","volume":"14","author":"Gavory","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0290","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1535-7163.MCT-20-0184","article-title":"Novel, selective inhibitors of USP7 uncover multiple mechanisms of antitumor activity in vitro and in vivo","volume":"19","author":"Ohol","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104751_b0295","doi-asserted-by":"crossref","first-page":"12502","DOI":"10.1021\/acs.jmedchem.6c00407","article-title":"Structure-guided discovery of OAT-4828 as potent, selective, and orally bioavailable USP7 inhibitor with in vivo antileukemic activity","volume":"69","author":"Chrzanowski","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0300","article-title":"The deubiquitylase USP9X controls ribosomal stalling","volume":"220","author":"Clancy","year":"2021","journal-title":"J Cell Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0305","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1038\/s44318-026-00742-y","article-title":"Global analysis of cancer cell responses to USP9X inhibition","volume":"45","author":"Schenk","year":"2026","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2026.104751_b0310","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104751_b0315","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41422-018-0091-x","article-title":"Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade","volume":"28","author":"Wang","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.drudis.2026.104751_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115369","article-title":"Structure-based discovery of potent USP28 inhibitors derived from Vismodegib","volume":"254","author":"Zhou","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0325","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1038\/s44319-024-00167-w","article-title":"Structural basis for the bi-specificity of USP25 and USP28 inhibitors","volume":"25","author":"Patzke","year":"2024","journal-title":"EMBO Rep"},{"key":"10.1016\/j.drudis.2026.104751_b0330","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/j.bmcl.2018.05.013","article-title":"Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy","volume":"28","author":"Kluge","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104751_b0335","doi-asserted-by":"crossref","first-page":"13645","DOI":"10.1021\/acs.jmedchem.2c00408","article-title":"Discovery of potent OTUB1\/USP8 dual inhibitors targeting proteostasis in non-small-cell lung cancer","volume":"65","author":"Tan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0340","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202101287","article-title":"Benchmarking a highly selective USP30 inhibitor for enhancement of mitophagy and pexophagy","volume":"5","author":"Rusilowicz-Jones","year":"2022","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.drudis.2026.104751_b0345","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41594-025-01534-4","article-title":"Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of the mitophagy regulator USP30","volume":"32","author":"Kazi","year":"2025","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0350","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302533","article-title":"Variety in the USP deubiquitinase catalytic mechanism","volume":"7","author":"Keijzer","year":"2024","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.drudis.2026.104751_b0355","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1019636","article-title":"Targeting the ubiquitin system by fragment-based drug discovery","volume":"9","author":"Kennedy","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.drudis.2026.104751_b0360","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11030-009-9187-z","article-title":"Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept","volume":"14","author":"Lisurek","year":"2010","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104751_b0365","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1021\/acschembio.0c00031","article-title":"Cyanopyrrolidine inhibitors of ubiquitin specific protease 7 mediate desulfhydration of the active-site cysteine","volume":"15","author":"Bashore","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0370","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s42004-025-01410-8","article-title":"Enantioselective OTUD7B fragment discovery through chemoproteomics screening and high-throughput optimisation","volume":"8","author":"Vuorinen","year":"2025","journal-title":"Commun Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0375","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202311190","article-title":"Discovery of a potent deubiquitinase (DUB) small-molecule activity-based probe enables broad spectrum DUB activity profiling in living cells","volume":"62","author":"Conole","year":"2023","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drudis.2026.104751_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109022","article-title":"Rational DESIGN and structure-activity relationship study of novel JOSD2 inhibitor against colorectal cancer","volume":"166","author":"Liu","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0385","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature24006","article-title":"USP7 small-molecule inhibitors interfere with ubiquitin binding","volume":"550","author":"Kategaya","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104751_b0390","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41594-025-01517-5","article-title":"Molecular glues that inhibit deubiquitylase activity and inflammatory signaling","volume":"32","author":"Chandler","year":"2025","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0395","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1021\/acs.jmedchem.1c00889","article-title":"Structure\u2013activity relationship of USP5 inhibitors","volume":"64","author":"Mann","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0400","doi-asserted-by":"crossref","first-page":"18993","DOI":"10.1021\/acs.jmedchem.4c01472","article-title":"Structure-guided discovery of selective USP7 Inhibitors with in vivo activity","volume":"67","author":"Vasas","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0405","doi-asserted-by":"crossref","first-page":"16622","DOI":"10.1021\/acs.jmedchem.2c01444","article-title":"Discovery of orally bioavailable N-benzylpiperidinol derivatives as potent and selective USP7 inhibitors with in vivo antitumor immunity activity against colon cancer","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105300","article-title":"Ubiquitin-specific protease 11 structure in complex with an engineered substrate mimetic reveals a molecular feature for deubiquitination selectivity","volume":"299","author":"Maurer","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0415","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/ph15050646","article-title":"Drug design by pharmacophore and virtual screening approach","volume":"15","author":"Giordano","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104751_b0420","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.3390\/ijms21165638","article-title":"Assay systems for profiling deubiquitinating activity","volume":"21","author":"Cho","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104751_b0425","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s11030-022-10523-4","article-title":"Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices","volume":"27","author":"Oyedele","year":"2023","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104751_b0430","doi-asserted-by":"crossref","DOI":"10.3389\/fbinf.2022.885983","article-title":"Scoring functions for protein-ligand binding affinity prediction using structure-based deep learning: a review","volume":"2","author":"Meli","year":"2022","journal-title":"Front Bioinformatics"},{"key":"10.1016\/j.drudis.2026.104751_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemolab.2024.105278","article-title":"A review of quantitative structure-activity relationship: the development and current status of data sets, molecular descriptors and mathematical models","volume":"256","author":"Li","year":"2025","journal-title":"Chemom Intell Lab Syst"},{"key":"10.1016\/j.drudis.2026.104751_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44386-024-00001-2","article-title":"Structure and dynamics in drug discovery","volume":"1","author":"Wei","year":"2024","journal-title":"NPJ Drug Discov"},{"key":"10.1016\/j.drudis.2026.104751_b0445","first-page":"684","article-title":"Potential inhibitors of the OTUB1 catalytic site to develop an anti-cancer drug using in-silico approaches","volume":"11","author":"Galindo-Hern\u00e1ndez","year":"2023","journal-title":"Rep Biochem Mol Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108397","article-title":"Structure-based virtual screening of novel USP5 inhibitors targeting the zinc finger ubiquitin-binding domain","volume":"174","author":"Wang","year":"2024","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.drudis.2026.104751_b0455","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41419-023-05900-2","article-title":"Discovery of an OTUD3 inhibitor for the treatment of non-small cell lung cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104751_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100609","article-title":"Structural premise of selective deubiquitinase USP30 inhibition by small-molecule benzosulfonamides","volume":"22","author":"O'Brien","year":"2023","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.drudis.2026.104751_b0465","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf533","article-title":"Computational toxicology in drug discovery: applications of artificial intelligence in ADMET and toxicity prediction","volume":"26","author":"Zhang","year":"2025","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.drudis.2026.104751_b0470","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.molcel.2018.10.045","article-title":"USP1 is required for replication fork protection in BRCA1-deficient tumors","volume":"72","author":"Lim","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104751_b0475","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1016\/j.molcel.2021.08.016","article-title":"REV1-Pol\u03b6 maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps","volume":"81","author":"Taglialatela","year":"2021","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104751_b0480","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molcel.2016.12.020","article-title":"Forging ahead through darkness: PCNA, still the principal conductor at the replication fork","volume":"65","author":"Choe","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104751_b0485","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1535-7163.MCT-22-0409","article-title":"Ubiquitinated PCNA drives USP1 synthetic lethality in cancer","volume":"22","author":"Simoneau","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104751_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130262","article-title":"Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor","volume":"124","author":"Throner","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104751_b0495","article-title":"UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas","volume":"5","author":"Liu","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2026.104751_b0500","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/s41467-019-10824-7","article-title":"The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis","volume":"10","author":"Du","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104751_b0505","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1080\/17425247.2020.1798401","article-title":"Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy","volume":"17","author":"Kumar","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.drudis.2026.104751_b0510","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1097-2765(04)00157-1","article-title":"A dynamic role of HAUSP in the p53-Mdm2 pathway","volume":"13","author":"Li","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104751_b0515","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104751_b0520","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/bjh.19492","article-title":"Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia","volume":"204","author":"Xu","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2026.104751_b0525","series-title":"Vasculopathies: Behavioral, Chemical, Environmental, and Genetic Factors","first-page":"1","article-title":"(2018) Cardiovascular disease: an introduction","author":"Thiriet","year":"2018"},{"key":"10.1016\/j.drudis.2026.104751_b0530","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41440-024-01581-2","article-title":"Administration of USP7 inhibitor p22077 alleviates Angiotensin II (Ang II)-induced atrial fibrillation in mice","volume":"47","author":"Wang","year":"2024","journal-title":"Hypertens Res"},{"key":"10.1016\/j.drudis.2026.104751_b0535","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1021361","article-title":"Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice","volume":"13","author":"Gu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104751_b0540","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/FJC.0000000000001640","article-title":"Deubiquitinase USP47 ameliorates cardiac hypertrophy through reducing protein O-GlcNAcylation","volume":"85","author":"Jiang","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.drudis.2026.104751_b0545","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41420-022-01086-2","article-title":"Ubiquitin-specific protease 7 regulates myocardial ischemia\/reperfusion injury by stabilizing Keap1","volume":"8","author":"Xu","year":"2022","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2026.104751_b0550","doi-asserted-by":"crossref","first-page":"7914","DOI":"10.1021\/acs.jmedchem.5c00102","article-title":"Ubiquitin-specific protease 7 (USP7) as a promising therapeutic target for drug discovery: from mechanisms to therapies","volume":"68","author":"Song","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0555","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41440-019-0354-z","article-title":"Inhibition of UCHL1 by LDN-57444 attenuates Ang II-induced atrial fibrillation in mice","volume":"43","author":"Bi","year":"2020","journal-title":"Hypertens Res"},{"key":"10.1016\/j.drudis.2026.104751_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174045","article-title":"UCHL1 inhibition attenuates cardiac fibrosis via modulation of nuclear factor-\u03baB signaling in fibroblasts","volume":"900","author":"Gong","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104751_b0565","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.7150\/thno.99340","article-title":"Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21","volume":"14","author":"Han","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2026.104751_b0570","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu8422","article-title":"Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3","volume":"11","author":"Ye","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2026.104751_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115746","article-title":"Otilonium Bromide acts as a selective USP28 inhibitor and exhibits cytotoxic activity against multiple human cancer cell lines","volume":"215","author":"Xu","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2026.104751_b0580","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/CIRCRESAHA.122.321849","article-title":"USP25 ameliorates pathological cardiac hypertrophy by stabilizing SERCA2a in cardiomyocytes","volume":"132","author":"Ye","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2026.104751_b0585","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12975-023-01228-3","article-title":"Inhibition of USP30 promotes mitophagy by regulating ubiquitination of MFN2 by Parkin to attenuate early brain injury after SAH","volume":"16","author":"Liu","year":"2025","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.drudis.2026.104751_b0590","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41419-024-06439-6","article-title":"USP30 inhibition induces mitophagy and reduces oxidative stress in parkin-deficient human neurons","volume":"15","author":"Okarmus","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104751_b0595","article-title":"Neuroinflammation inhibition by small-molecule targeting USP7 noncatalytic domain for neurodegenerative disease therapy","volume":"8","author":"Zhang","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2026.104751_b0600","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152170","article-title":"USP25 inhibition ameliorates Alzheimer\u2019s pathology through the regulation of APP processing and A\u03b2 generation","volume":"132","author":"Zheng","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2026.104751_b0605","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nature13418","article-title":"The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy","volume":"510","author":"Bingol","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104751_b0610","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41573-024-01105-0","article-title":"Targeting mitophagy in neurodegenerative diseases","volume":"24","author":"Antico","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104751_b0615","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe1340","article-title":"Trisomy 21\u2013induced dysregulation of microglial homeostasis in Alzheimer\u2019s brains is mediated by USP25","volume":"7","author":"Zheng","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2026.104751_b0620","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1073\/pnas.84.7.1829","article-title":"Ubiquitin-aldehyde: a general inhibitor of ubiquitin-recycling processes","volume":"84","author":"Hershko","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104751_b0625","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1021\/acs.jmedchem.4c02760","article-title":"Covalent-allosteric inhibitors: do we get the best of both worlds?","volume":"68","author":"Tao","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0630","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.pbio.0020002","article-title":"JAMM: a metalloprotease-like zinc site in the proteasome and signalosome","volume":"2","author":"Ambroggio","year":"2003","journal-title":"PLoS Biol"},{"key":"10.1016\/j.drudis.2026.104751_b0635","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/0076-6879(94)44035-2","article-title":"Catalytic mechanism in papain family of cysteine peptidases","volume":"244","author":"Storer","year":"1994","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.drudis.2026.104751_b0640","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1039\/C6CS00083E","article-title":"Chemical and semisynthetic approaches to study and target deubiquitinases","volume":"45","author":"Gopinath","year":"2016","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104751_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117872","article-title":"Therapeutic targeting of ubiquitin-specific protease 7 (USP7): mechanistic insights, dysregulation, and advances in drug discovery","volume":"296","author":"El-Hamaky","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0650","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1134\/S1068162023020073","article-title":"Recent progress of ubiquitin-specific-processing protease 7 inhibitors","volume":"49","author":"Chi","year":"2023","journal-title":"Russ J Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0655","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1038\/s41467-025-56981-w","article-title":"USP7 V517F mutation as a mechanism of inhibitor resistance","volume":"16","author":"Miao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104751_b0660","doi-asserted-by":"crossref","first-page":"19209","DOI":"10.1074\/jbc.M117.815126","article-title":"An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons","volume":"292","author":"Boselli","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104751_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112967","article-title":"MF-094, a potent and selective USP30 inhibitor, accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome","volume":"410","author":"Li","year":"2022","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.drudis.2026.104751_b0670","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1158\/1535-7163.MCT-13-0103-T","article-title":"Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells","volume":"12","author":"Mistry","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104751_b0675","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1158\/1538-7445.AM2024-7146","article-title":"Abstract 7146: HSK39775: a USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104751_b0680","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1158\/1538-7445.AM2025-5723","article-title":"Abstract 5723: XL309 is a potent, selective, and orally bioavailable USP1 inhibitor active as monotherapy and in combination with PARP inhibitors or irinotecan","volume":"85","author":"Charruyer-Reinwald","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104751_b0685","doi-asserted-by":"crossref","first-page":"LB271","DOI":"10.1158\/1538-7445.AM2024-LB271","article-title":"Abstract LB271: Synergistic anti-tumor efficacy in olaparib-sensitive and -resistant models via simultaneously inhibition of USP1 and PARP","volume":"84","author":"Yang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104751_b0690","doi-asserted-by":"crossref","first-page":"B054","DOI":"10.1158\/1535-7163.TARG-23-B054","article-title":"Abstract B054: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair","volume":"22","author":"Simoneau","year":"2023","journal-title":"Mol Cancer Ther"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:22:23Z","timestamp":1790094143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462600156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":138,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S135964462600156X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104751","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104751"}}